Study of PBF-999 in Solid Tumour Advanced Cancer

Inclusion Criteria:

* Advanced/metastatic histologically confirmed solid tumor
* At least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
* Patients who has progressed to the standard therapy
* ECOG performance status of 0/1
* Age greater than 18 years.
* Adequate bone marrow, renal and hepatic function
* Able and willing to give valid written consent for available archival tumor samples (not mandatory) and tumor biopsies before and during protocol (immune)therapy (not mandatory but highly recommended).
* Prior immunotherapy is allowed

Exclusion Criteria:

* Participation in another clinical study with an investigational product during the last 4 weeks or 5 half-lifes prior to starting on treatment.
* Symptomatic and/or untreated Brain Metastases
* Pregnancy or breast feeding
* Serious uncontrolled medical disorder or active infection that in the investigator's opinion would impair the patient's ability to receive study treatment.
* Concurrent use of other anticancer approved or investigational agents is not allowed.
* Active or prior documented autoimmune disease within the past 2 years. NOTE: Patients with vitiligo, Grave's disease, or psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.
* Prior malignancy in past 2 years or as identified in Section 7.2 of this protocol
* Patients receiving systemic steroids ≥ 10mg/day of prednisone or the equivalent
* Concurrent administration of strong inhibitors or moderate inducers of CYP1A2 is not permitted; administration must be discontinued at least 7 days prior to initiating study drug administration.